CSPIA
AUPH icon

Cary Street Partners Investment Advisory’s Aurinia Pharmaceuticals AUPH Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,560
Closed -$12.1K – 709
2023
Q3 		$12.1K Hold
1,560
– – ﹤0.01% 1241
2023
Q2 		$15.1K Hold
1,560
– – ﹤0.01% 1128
2023
Q1 		$17.1K Hold
1,560
– – ﹤0.01% 1020
2022
Q4 		$6.74K Buy
+1,560
New +$9.05K ﹤0.01% 1248

Other funds holding AUPH

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Cary Street Partners Investment Advisory's AUPH Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2023, closing a stake of 1,560 shares — an estimated $12.1K sold.

Cary Street Partners Investment Advisory first reported a position in AUPH in Q4 2022 and held it in 4 quarters. The position peaked at $17.1K in Q1 2023. 191 funds tracked by Wall St. Rank hold AUPH as of Q4 2023.

  • Cary Street Partners Investment Advisory reported no remaining Aurinia Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 1,560 Aurinia Pharmaceuticals shares in Q4 2023, an estimated $12.1K.
  • Cary Street Partners Investment Advisory first reported a position in Aurinia Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Cary Street Partners Investment Advisory's Aurinia Pharmaceuticals position peaked at $17.1K in Q1 2023.
  • 191 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.